GlassScriptPhysician profile
Liqiao Ma
NPI 1174941835
$8,962.96
in general payments reported to CMS, 2019-2025
36 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,502 · 2020: $580 · 2021: $736 · 2022: $917 · 2023: $1,118 · 2024: $1,763 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,202 · Education: $27.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,201.68 |
| Education | $27.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,587.18 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,013.03 | 2019-2025 | |
| Janssen Biotech, INC. | $740.07 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Genzyme Corporation | $678.15 | 2019-2025 | |
| Lilly USA, LLC | $644.68 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $538.99 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $511.96 | 2019-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $392.00 | 2019-2025 | Absorica Ld, Winlevi |
| Janssen Scientific Affairs, LLC | $353.55 | 2019 | |
| Ucb, INC. | $265.74 | 2023-2025 | Bimzelx |
| Dermavant Sciences, INC. | $254.51 | 2022-2024 | Vtama |
| Amgen INC. | $224.00 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $217.00 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $183.42 | 2019-2025 | Cabtreo, Arazlo |
| Incyte Corporation | $179.13 | 2021-2025 | Opzelura |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $170.30 | 2023-2024 | Zoryve |
| Galderma Laboratories, L.P. | $163.09 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $160.31 | 2022-2025 | Sotyktu |
| Genentech USA, INC. | $81.04 | 2021-2022 | |
| Almirall LLC | $80.44 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $73.65 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2021 | |
| Dermira, INC. | $54.17 | 2019-2021 | |
| Organogenesis INC. | $52.66 | 2024 | Affinity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.97 | 2023-2024 | Spevigo |
| Kerecis Limited | $35.48 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Paratek Pharmaceuticals, INC. | $33.59 | 2024 | Nuzyra |
| Celgene Corporation | $32.67 | 2019 | |
| Organon LLC | $27.07 | 2025 | Vtama |
| Biofrontera INC. | $22.44 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Solventum Corporation | $16.58 | 2024 | Kerramax Care, Activ.A.C., Promogran Prisma |
| Merck Sharp & Dohme LLC | $16.35 | 2019 | |
| Mission Pharmacal Company | $16.09 | 2021 | |
| Epi Health, LLC | $15.10 | 2022 | |
| Dusa Pharmaceuticals, INC. | $14.10 | 2019 | |
| Merz North America, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liqiao Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.